Tag: HRT
-
CHMP January 2026 Highlights: Six Medicines Recommended for Approval
Overview of CHMP January 2026 Highlights The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) concluded its January 26–29, 2026 meeting with a landmark outcome: six medicines were recommended for approval. This decision, if adopted by the European Commission, would bring new therapies to patients across a range of conditions. The CHMP…
-
NHS Warns Mounjaro Users About Interactions with Oral Medications
Overview: What the NHS is warning about The NHS has issued guidance for people using Mounjaro (tirzepatide) as part of its growing role in weight management. While the diabetes and obesity drug can help suppress appetite by delaying gastric emptying, this very mechanism can also alter how quickly and effectively oral medications are absorbed. In…
-
NHS Warns Mounjaro Users About Effects on Oral Medications
Overview: NHS warns on Mounjaro and oral medications The NHS has issued guidance for people using Mounjaro (tirzepatide) as part of a weight loss or diabetes management plan who also rely on oral medications such as contraceptives or hormone replacement therapy (HRT). While Mounjaro is effective at slowing gastric emptying to suppress appetite and regulate…
-
FDA’s New Labeling: No More Black Box Warnings for Menopause Hormone Therapy
Overview: A Shift in How Menopause Hormone Therapy Is Labeled The FDA has announced a major update to the labeling of menopause hormone therapies, removing the long-standing black box warnings about potential risks such as breast cancer, heart disease, and dementia. The change aims to provide clearer, more balanced information to patients and clinicians, emphasizing…
-
FDA Moves to Remove Black Box Warnings From Menopause Hormone Therapies
FDA Announces Removal of Black Box Warnings From Menopause Hormone Therapies The U.S. Food and Drug Administration (FDA) has announced plans to remove the black box warnings associated with menopause hormone therapies. These warnings, once highlighted as the most serious safety information on medication labels, detailed potential risks related to breast cancer, heart disease, and…
-
FDA Softens Stance on Menopause Hormone Therapies: What Changed and Why
What the FDA decision means for menopause treatment The U.S. Food and Drug Administration has announced a pivotal update to the labeling of menopause hormone therapies (HRT). Historic labels carried a black box warning about several serious health risks, including breast cancer, heart disease, and dementia. The FDA’s new approach no longer uses that singular,…
-
Ireland study suggests HRT after menopause may lower dementia risk for women
New Irish findings connect lifetime oestrogen exposure and dementia risk A new study from Ireland suggests that women who maintain higher exposure to oestrogen across their lives—and those who use hormone replacement therapy (HRT) after menopause—may face a lower risk of developing dementia. Led by Dr Emer McGrath, an associate professor of medicine at the…
-
Women and Menopause: Could HRT After Menopause Lower Dementia Risk, Irish Study Suggests
New insights on estrogen, cognition, and dementia risk Autsome women’s health research in Ireland is shedding light on how lifetime exposure to oestrogen might influence brain aging. An Irish study from the University of Galway, led by Dr. Emer McGrath, analyzed reproductive and hormonal factors across a woman’s life to uncover connections with cognitive outcomes…
-
HRT After Menopause Linked to Lower Dementia Risk in Irish Study
Overview A new Irish study suggests that women who take hormone replacement therapy (HRT) after menopause may have a reduced risk of developing dementia. The research, led by University of Galway associate professor Dr. Emer McGrath, examined how lifetime exposure to oestrogen from various sources could influence brain aging and cognitive function. What the study…
-
Veteran Singapore Doctor Suspended for Inappropriate Hormone Therapy Prescriptions
Overview: A Long-Standing Medical Practice Questioned A veteran doctor in Singapore, Dr Wong Yoke Meng, with more than four decades in medicine, has been suspended for 36 months following a disciplinary tribunal ruling that found him guilty of professional misconduct related to hormone replacement therapies (HRT). The case, which involved 18 patients and spanned 2013…